May 5-7: ATVB/PVD, Nashville, TN: RVX Poster presentation on one of the days.

163. Apabetalone (RVX-208) Has Anti-atherosclerotic, AntiThrombotic and Anti-Inflammatory Effects in Patients With Cardiovascular Disease (CVD)

Ewelina Kulikowski, Sylwia Wasiak, Dean Gilham, Cyrus Calosing, Laura Tsujikawa, Christopher Halliday, Resverlogix Corp, Calgary, AB, Canada; Jan Johansson, Mike Sweeney, Resverlogix Corp, San Francisco, CA; Norman C Wong, Health Science Ctr., Calgary, AB, Canada

May 21-24: ERA/EDTA, Vienna, Austria: Pending response from Sarah whether RVX is presenting

May 29-June 1: EAS 2016, Innsbruck, Austria: RVX Oral presentation

YIS03 Young Investigator Session

Clinical Epidemiology and Pharmacology

30-May-2016 17:00 18:30

Abstract:

APABETALONE (RVX-208) DECREASES ATHEROGENIC, THROMBOTIC AND INFLAMMATORY MEDIATORS IN VITRO AND IN PLASMA OF PATIENTS WITH CARDIOVASCULAR DISEASE (CVD).

Co-authors: N. Wong, E. Kulikowski, S. Wasiak, D. Gilham, C. Calosing, T. Laura, C. Halliday, J. Johansson, M. Sweeney

June 3-7: ASCO 2016, Chicago, IL: Pending response from Sarah whether Zenith is presenting

June 6-9: BIO International Convention, San Francisco, CA: Pending response from Sarah whether RVX or Zenith are presenting or just attending. Both RVX and Zenith have the BIO International Convention 2016 event on their respective websites. The attendee list (current as of April 4, 2016) lists Resverlogix but not Zenith. This list shows that for RVX there are 5 attendees: 1) President & CEO; 2) SVP, Business & Market Development; 3) Vice President of Scientific Development; 4) Senior VP Medical Affairs; 5) Senior Vice President of Clinical Development.

June 10-14: ADA Scientific Sessions, New Orleans, LA: Pending response from Sarah whether RVX is presenting